Skip to main content
Top
Published in: Diabetologia 9/2015

01-09-2015 | Article

Increased aortic stiffness predicts future development and progression of peripheral neuropathy in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study

Authors: Claudia R. L. Cardoso, Camila B. M. Moran, Fernanda S. Marinho, Marcel T. Ferreira, Gil F. Salles

Published in: Diabetologia | Issue 9/2015

Login to get access

Abstract

Aims/hypothesis

Diabetic peripheral neuropathy (DPN) is a chronic microvascular complication that is strongly associated with poor glycaemic control and also with a worse prognosis. We aimed to evaluate the predictors of the development and progression of DPN in a cohort of high-risk patients with type 2 diabetes.

Methods

In a prospective study, 477 patients with type 2 diabetes were clinically assessed for the presence of DPN at baseline and after a median follow-up of 6.2 years (range 2–10 years). Clinical laboratory data were obtained at study entry and throughout the follow-up. Aortic stiffness was assessed by the carotid–femoral pulse wave velocity (cf-PWV) at baseline. Multivariate Poisson regression analysis was used to examine independent predictors of the development/progression of DPN.

Results

At baseline, 135 patients (28%) had DPN, and during follow-up 97 patients (20%) had either a new development or a worsening of DPN. Patients who showed a development or progression of DPN were taller and had a longer duration of diabetes, a greater prevalence of other microvascular complications and hypertension, greater aortic stiffness and poorer glycaemic control than patients who did not have new or progressive neuropathy. After adjustments for the baseline prevalence of DPN, the patient’s age and sex, and the time interval between DPN assessments; an increased aortic stiffness (cf-PWV >10 m/s) were predictive of new/progressive DPN (incidence rate ratio 2.04, 95% CI 1.28, 3.23; p = 0.002). Other independent predictors were the mean first-year HbA1c level (p = 0.05), nephropathy (p = 0.006), arterial hypertension (p = 0.06) and height (p = 0.03).

Conclusions/interpretation

Increased aortic stiffness at baseline predicts the future development or progression of peripheral neuropathy, independent of diabetic metabolic control, suggesting a physiopathological link between macrovascular and microvascular abnormalities in type 2 diabetes.
Literature
1.
go back to reference Tesfaye S, Boulton AJ, Dyck PJ et al (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33:2285–2293PubMedCentralPubMedCrossRef Tesfaye S, Boulton AJ, Dyck PJ et al (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33:2285–2293PubMedCentralPubMedCrossRef
2.
go back to reference Cameron NE, Eaton SE, Cotter MA, Tesfaye S (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44:1973–1988PubMedCrossRef Cameron NE, Eaton SE, Cotter MA, Tesfaye S (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44:1973–1988PubMedCrossRef
3.
go back to reference Giannini C, Dyck PJ (1994) Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus. Ann Neurol 36:408–415PubMedCrossRef Giannini C, Dyck PJ (1994) Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus. Ann Neurol 36:408–415PubMedCrossRef
4.
go back to reference Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH (2000) Showing neuropathy is related to increased mortality in diabetic patients—a survival analysis using an accelerated failure time model. J Clin Epidemiol 53:519–523PubMedCrossRef Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH (2000) Showing neuropathy is related to increased mortality in diabetic patients—a survival analysis using an accelerated failure time model. J Clin Epidemiol 53:519–523PubMedCrossRef
5.
go back to reference Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J (2005) The global burden of diabetic foot disease. Lancet 366:1719–1724PubMedCrossRef Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J (2005) The global burden of diabetic foot disease. Lancet 366:1719–1724PubMedCrossRef
6.
go back to reference Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA (2003) The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26:1790–1795PubMedCrossRef Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA (2003) The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26:1790–1795PubMedCrossRef
7.
go back to reference Albers JW, Herman WH, Pop-Busui R, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group et al (2010) Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33:1090–1096PubMedCentralPubMedCrossRef Albers JW, Herman WH, Pop-Busui R, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group et al (2010) Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33:1090–1096PubMedCentralPubMedCrossRef
8.
go back to reference Tesfaye S, Chaturvedi N, Eaton SE, EURODIAB Prospective Complications Study Group et al (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352:341–350PubMedCrossRef Tesfaye S, Chaturvedi N, Eaton SE, EURODIAB Prospective Complications Study Group et al (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352:341–350PubMedCrossRef
9.
go back to reference Ismail-Beigi F, Craven T, Banerji MA, ACCORD trial group et al (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376:419–430PubMedCentralPubMedCrossRef Ismail-Beigi F, Craven T, Banerji MA, ACCORD trial group et al (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376:419–430PubMedCentralPubMedCrossRef
10.
go back to reference Charles M, Ejskjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A (2011) Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 34:2244–2249PubMedCentralPubMedCrossRef Charles M, Ejskjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A (2011) Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 34:2244–2249PubMedCentralPubMedCrossRef
11.
go back to reference Pop-Busui R, Lu J, Brooks MM, BARI 2D Study Group et al (2013) Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care 36:3208–3215PubMedCentralPubMedCrossRef Pop-Busui R, Lu J, Brooks MM, BARI 2D Study Group et al (2013) Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care 36:3208–3215PubMedCentralPubMedCrossRef
12.
13.
go back to reference Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH (2011) Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 57:1511–1522PubMedCrossRef Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH (2011) Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 57:1511–1522PubMedCrossRef
14.
go back to reference Kimoto E, Shoji T, Shinohara K et al (2003) Preferential stiffening of central over peripheral arteries in type 2 diabetes. Diabetes 52:448–452PubMedCrossRef Kimoto E, Shoji T, Shinohara K et al (2003) Preferential stiffening of central over peripheral arteries in type 2 diabetes. Diabetes 52:448–452PubMedCrossRef
15.
go back to reference Cardoso CR, Ferreira MT, Leite NC, Barros PN, Conte PH, Salles GF (2009) Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients. Atherosclerosis 205:472–476PubMedCrossRef Cardoso CR, Ferreira MT, Leite NC, Barros PN, Conte PH, Salles GF (2009) Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients. Atherosclerosis 205:472–476PubMedCrossRef
16.
go back to reference Kim ES, Moon SD, Kim HS et al (2011) Diabetic peripheral neuropathy is associated with increased arterial stiffness without changes in carotid intima-media thickness in type 2 diabetes. Diabetes Care 34:1403–1405PubMedCentralPubMedCrossRef Kim ES, Moon SD, Kim HS et al (2011) Diabetic peripheral neuropathy is associated with increased arterial stiffness without changes in carotid intima-media thickness in type 2 diabetes. Diabetes Care 34:1403–1405PubMedCentralPubMedCrossRef
17.
go back to reference Laurent S, Cockcroft J, van Bortel L et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605PubMedCrossRef Laurent S, Cockcroft J, van Bortel L et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605PubMedCrossRef
18.
go back to reference Cardoso CR, Ferreira MT, Leite NC, Salles GF (2013) Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetes Care 36:3772–3778PubMedCentralPubMedCrossRef Cardoso CR, Ferreira MT, Leite NC, Salles GF (2013) Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetes Care 36:3772–3778PubMedCentralPubMedCrossRef
19.
go back to reference Cardoso CR, Leite NC, Ferreira MT, Salles GF (2015) Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Acta Diabetol 52:21–29PubMedCrossRef Cardoso CR, Leite NC, Ferreira MT, Salles GF (2015) Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Acta Diabetol 52:21–29PubMedCrossRef
20.
go back to reference Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR (2013) Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens 31:2176–2186PubMedCrossRef Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR (2013) Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens 31:2176–2186PubMedCrossRef
21.
go back to reference Van Bortel LM, Laurent S, Boutouyrie P, Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries et al (2012) Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 30:445–448PubMedCrossRef Van Bortel LM, Laurent S, Boutouyrie P, Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries et al (2012) Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 30:445–448PubMedCrossRef
22.
go back to reference Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH (1993) A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:150–154PubMedCrossRef Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH (1993) A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:150–154PubMedCrossRef
23.
go back to reference Symons MJ, Moore DT (2002) Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol 55:893–899PubMedCrossRef Symons MJ, Moore DT (2002) Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol 55:893–899PubMedCrossRef
24.
go back to reference Yokoyama H, Yokota Y, Tada J, Kanno S (2007) Diabetic neuropathy is closely associated with arterial stiffening and thickness in type 2 diabetes. Diabet Med 24:1329–1335PubMedCrossRef Yokoyama H, Yokota Y, Tada J, Kanno S (2007) Diabetic neuropathy is closely associated with arterial stiffening and thickness in type 2 diabetes. Diabet Med 24:1329–1335PubMedCrossRef
25.
go back to reference Laurent S, Boutouyrie P (2007) Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension 49:1202–1206PubMedCrossRef Laurent S, Boutouyrie P (2007) Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension 49:1202–1206PubMedCrossRef
26.
go back to reference Ferreira MT, Leite NC, Cardoso CR, Salles GF (2015) Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycemic control. The Rio de Janeiro type 2 diabetes cohort study. Diabetes Care 38:897–904PubMedCrossRef Ferreira MT, Leite NC, Cardoso CR, Salles GF (2015) Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycemic control. The Rio de Janeiro type 2 diabetes cohort study. Diabetes Care 38:897–904PubMedCrossRef
27.
go back to reference Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ (1997) Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 46:665–670PubMedCrossRef Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ (1997) Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 46:665–670PubMedCrossRef
28.
go back to reference Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group (2014) Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:31–38PubMedCentralPubMedCrossRef Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group (2014) Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:31–38PubMedCentralPubMedCrossRef
29.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef
30.
go back to reference Duckworth W, Abraira C, Moritz T, Investigators VADT et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRef Duckworth W, Abraira C, Moritz T, Investigators VADT et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRef
31.
go back to reference Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M (1995) Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:89–94PubMedCrossRef Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M (1995) Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:89–94PubMedCrossRef
32.
go back to reference Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG (1997) Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 20:1162–1167PubMedCrossRef Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG (1997) Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 20:1162–1167PubMedCrossRef
33.
go back to reference van de Poll-Franse LV, Valk GD, Renders CM, Heine RJ, van Eijk JT (2002) Longitudinal assessment of the development of diabetic polyneuropathy and associated risk factors. Diabet Med 19:771–776PubMedCrossRef van de Poll-Franse LV, Valk GD, Renders CM, Heine RJ, van Eijk JT (2002) Longitudinal assessment of the development of diabetic polyneuropathy and associated risk factors. Diabet Med 19:771–776PubMedCrossRef
34.
go back to reference Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR (2002) UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25:894–899PubMedCrossRef Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR (2002) UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25:894–899PubMedCrossRef
Metadata
Title
Increased aortic stiffness predicts future development and progression of peripheral neuropathy in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study
Authors
Claudia R. L. Cardoso
Camila B. M. Moran
Fernanda S. Marinho
Marcel T. Ferreira
Gil F. Salles
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 9/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3658-9

Other articles of this Issue 9/2015

Diabetologia 9/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.